Study on key problems of personalized 131I-iodine therapy for patients with Graves disease hyperthyroidism

Precise 131I-iodine therapy for patients with Graves disease hyperthyroidism

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPd-16008303

Enrollment

Unknown

Registered

2016-04-18

Start date

2016-04-18

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves disease with hyperthyroidism

Interventions

high dose:High dose 131-iodine

medium dose:Medium dose 131-iodine

low dose:Low dose 131-iodine

Eligibility

Sex/Gender

All

Age

20 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Older than 20-year-old; 2. Thyroid volume 20 to 80mL, soft texture; 3. upper limited level 40%; 6. discontinue methimazole>5d; 7. low iodine diet>14d; 8. Follow the radiation protection rules.

Exclusion criteria

Exclusion criteria: 1. pregnant, lactation; 2. Graves disease with (suspective) thyroid cancer; 3. cannot follow the radiation protection rulus; 4. severe exophthalmos according to EUGOGO, 2006.

Design outcomes

Primary

Measure	Time frame
thyroid volume;thyroid function;	—

Secondary

Measure	Time frame
Tg;TgAb;TPOAb;TRAb;thyroid uptake rate;effective half life in thyroid;	—

Countries

China

Contacts

Public ContactYANGCHUN CHEN

Quanzhou First Hospital

1526797743@QQ.COM+86 18120625062

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026